Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP321 + Pembrolizumab in Advanced Melanoma
NCT02676869Phase 1Completed
- Sponsor
- Immutep Limited
- Start
- Apr 2016
- Primary completion
- Aug 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eftilagimod alpha in melanoma, sponsored by Immutep Limited. Primary endpoints: Recommended Phase 2 Dose and Frequency of Adverse Events. Started Apr 2016; status: completed.
02
Drugs
eftilagimod alpha
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02676869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676869.